Quanterix [QTRX] vs Boston Scientific [BSX] Detailed Stock Comparison
Quanterix
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Quanterix wins in 7 metrics, Boston Scientific wins in 11 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Quanterix | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -4.91 | 61.76 | Quanterix |
| Price-to-Book Ratio | 0.67 | 6.85 | Quanterix |
| Debt-to-Equity Ratio | 12.15 | 53.09 | Quanterix |
| PEG Ratio | -0.02 | 0.42 | Quanterix |
| EV/EBITDA | -0.14 | 34.95 | Quanterix |
| Profit Margin (TTM) | -56.05% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | -86.17% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | N/A | 18.63% | N/A |
| Return on Equity | -22.41% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | -10.28% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $-38.53M | $2.37B | Boston Scientific |
| 1-Year Return | -64.15% | 32.89% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 1.86 | 8.31 | Quanterix |
| Enterprise Value | $8.09M | $164.42B | Boston Scientific |
| EV/Revenue Ratio | 0.06 | 8.89 | Quanterix |
| Gross Profit Margin (TTM) | 46.12% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $3 | $13 | Boston Scientific |
| Earnings per Share (Diluted) | $-1.81 | $1.68 | Boston Scientific |
| Beta (Stock Volatility) | 1.07 | 0.66 | Boston Scientific |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Quanterix vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Quanterix | -1.43% | 6.61% | -6.56% | 0.62% | -35.89% | -55.02% |
| Boston Scientific | -0.79% | 1.02% | 1.38% | 0.54% | 0.69% | 17.71% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Quanterix | -64.15% | -48.95% | -86.28% | -73.38% | -73.38% | -73.38% |
| Boston Scientific | 32.89% | 159.65% | 156.42% | 516.34% | 1,816.39% | 301.11% |
Performance & Financial Health Analysis: Quanterix vs Boston Scientific
| Metric | QTRX | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $233.72M | $153.73B |
| Market Cap Category | Micro cap | Large cap |
| 10 Day Avg. Volume | 1,035,100 | 6,087,580 |
| 90 Day Avg. Volume | 802,360 | 7,069,760 |
| Last Close | $4.84 | $105.21 |
| 52 Week Range | $4.05 - $15.85 | $78.30 - $108.94 |
| % from 52W High | -69.47% | -3.42% |
| All-Time High | $92.57 (Feb 15, 2021) | $108.94 (Jul 23, 2025) |
| % from All-Time High | -94.77% | -3.42% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.29% | 0.23% |
| Quarterly Earnings Growth | -0.28% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.56% | 0.14% |
| Operating Margin (TTM) | -0.86% | 0.19% |
| Return on Equity (TTM) | -0.22% | 0.12% |
| Debt to Equity (MRQ) | 12.15 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.52 | $15.14 |
| Cash per Share (MRQ) | $5.62 | $0.36 |
| Operating Cash Flow (TTM) | $-29,592,000 | $4.28B |
| Levered Free Cash Flow (TTM) | $3.99M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Quanterix vs Boston Scientific
| Metric | QTRX | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -4.91 | 61.76 |
| Forward P/E | -5.72 | 37.19 |
| PEG Ratio | -0.02 | 0.42 |
| Price to Sales (TTM) | 1.86 | 8.31 |
| Price to Book (MRQ) | 0.67 | 6.85 |
| Market Capitalization | ||
| Market Capitalization | $233.72M | $153.73B |
| Enterprise Value | $8.09M | $164.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.06 | 8.89 |
| Enterprise to EBITDA | -0.14 | 34.95 |
| Risk & Other Metrics | ||
| Beta | 1.07 | 0.66 |
| Book Value per Share (MRQ) | $7.52 | $15.14 |
Financial Statements Comparison: Quanterix vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QTRX | BSX |
|---|---|---|
| Revenue/Sales | $24.45M | $4.66B |
| Cost of Goods Sold | $13.18M | $1.45B |
| Gross Profit | $11.28M | $3.21B |
| Research & Development | $9.08M | $443.00M |
| Operating Income (EBIT) | $-29.43M | $937.00M |
| EBITDA | $-23.18M | $1.23B |
| Pre-Tax Income | $-30.09M | $805.00M |
| Income Tax | $-73,000 | $133.00M |
| Net Income (Profit) | $-30.01M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QTRX | BSX |
|---|---|---|
| Cash & Equivalents | $76.51M | $725.00M |
| Total Current Assets | $335.00M | $7.34B |
| Total Current Liabilities | $40.40M | $5.06B |
| Long-Term Debt | $31.47M | $10.93B |
| Total Shareholders Equity | $316.39M | $22.45B |
| Retained Earnings | $-490.59M | $3.35B |
| Property, Plant & Equipment | $32.43M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QTRX | BSX |
|---|---|---|
| Operating Cash Flow | $-9.87M | $513.00M |
| Capital Expenditures | $-1.26M | $-187.00M |
| Free Cash Flow | $-15.14M | $277.00M |
| Debt Repayment | N/A | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | QTRX | BSX |
|---|---|---|
| Shares Short | 3.64M | 16.27M |
| Short Ratio | 5.61 | 2.15 |
| Short % of Float | 0.08% | 0.01% |
| Average Daily Volume (10 Day) | 1,035,100 | 6,087,580 |
| Average Daily Volume (90 Day) | 802,360 | 7,069,760 |
| Shares Outstanding | 38.54M | 1.47B |
| Float Shares | 39.88M | 1.48B |
| % Held by Insiders | 0.07% | 0.00% |
| % Held by Institutions | 0.74% | 0.94% |
Dividend Analysis & Yield Comparison: Quanterix vs Boston Scientific
| Metric | QTRX | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |